托伐普坦联合尿毒清颗粒治疗肾病综合征患者的临床研究

目的 分析托伐普坦联合尿毒清颗粒改善肾病综合征患者的肾功能、血脂、凝血以及生活质量的效果。 方法 选取2016年3月—2018年3月海南医学院第二附属医院收治的70例肾病综合征患者,根据随机数字表法分为2组,对照组35例患者采用托伐普坦治疗,观察组35例患者采用托伐普坦联合尿毒清颗粒治疗。比较2组治疗前后肾功能、血脂和凝血指标以及生活质量变化情况。 结果 治疗后,观察组Scr(73.16±8.82)μmol/L]、BUN(6.52±0.50)mmol/L]、24小时尿蛋白定量(1.21±0.44)g]均较对照组(84.36±9.68)μmol/L]、(7.28±0.67)mmol/L]、(1.89±0.58)g]明显降低,而ALB(39.77±4.45)g/L]较对照组(34.72±4.20)g/L]明显升高,差异具有统计学意义(均P<0.05);治疗后,2组患者的TG、TC、D-D水平较治疗前均明显降低;观察组Fib较治疗前明显降低,且观察组TG、TC、D-D、Fib均较对照组明显降低(均P<0.05);治疗后,2组患者的病情、体力、心理功能、一般生活功能、工作状况方面的生活质量评分较治疗前均明显升高;观察组病情、体力、心理功能、一般生活功能、工作状况方面的生活质量评分均较对照组明显升高(均P<0.05)。 结论 托伐普坦联合尿毒清颗粒治疗肾病综合征患者的临床效果显著,可有效提高患者肾功能,改善各血脂及凝血指标,提高患者生活质量。 

Clinical study of tolvaptan combined with Niaoduqing granule in the treatm ent of nephrotic syndrome

Objective To analyze the effect of tolvaptan combined with Niaoduqing granule on improving renal function, blood lipid, blood coagulation and quality of life in patients with nephrotic syndrome. Methods From March 2016 to March 2018, 70 patients with nephrotic syndrome in our hospital were divided into two groups according to the method of random number table. Thirty-five patients in the control group were treated with tovaptan, and 35 patients in the observation group were treated with tolvaptan and Niaoduqing granules. The renal function, blood lipid, coagulation index and quality of life of the two groups were compared before and after treatment. Results After treatment, Scr(73.16±8.82) μmol/L], BUN(6.52±0.50) mmol/L] and 24-hour urine protein quantity(1.21±0.44) g] in the observation group were significantly lower than those in the control group(84.36±9.68) μmol/L,(7.28±0.67) mmol/L and(1.89±0.58) g], and ALB(39.77±4.45) g/L was significantly higher than that in the control group(34.72±4.20) g/L. After treatment, TG, TC, D-D levels of the two groups were significantly lower than before treatment. FIB of the observation group was significantly lower than before treatment, and TG, TC, D-D, FIB of the observation group were significantly lower than that in the control group(all P<0.05). The quality of life scores of the observation group were significantly higher than that in the control group(all P<0.05). Conclusion The clinical effect of tolvaptan combined with Niaoduqing granules in the treatment of nephrotic syndrome is significant, which can effectively improve the renal function, improve the blood lipid and coagulation indexes, and improve the quality of life of patients.